What the research examined
A phase 2 study investigated adjunctive larazotide in children with multisystem inflammatory syndrome after COVID-19. Researchers measured circulating viral antigen, gastrointestinal symptoms, and recovery-related outcomes, reporting differences that warrant further investigation.
How to interpret the findings
MIS-C is a specific pediatric condition and should not be relabeled as general long COVID. A limited study cannot establish broad safety or effectiveness in other populations, and adjunctive research does not isolate the compound from all concurrent care.
Research literature
- Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.
Science translational medicine · 2025 · PMID 40737433
Links open the indexed paper records. Summaries are based on those records and their available abstracts, not a systematic review or a full-text appraisal of every study.